

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3147124

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SUNG WUK KIM	12/11/2014
SEUNG KOOK PARK	12/05/2014
YEON JUNG SONG	12/03/2014
EUN SUN KIM	12/03/2014
HYEA KYUNG AHN	12/03/2014
JAE KAP JEONG	12/03/2014
HUNG KEUN LEE	12/03/2014
RECEIVING PARTY DATA	
Name:	HANALL BIOPHARMA CO., LTD.
Street Address:	43, SANGSEODANG-1GIL, DAEDEOK-GU
City:	DAEGU
State/Country:	KOREA, REPUBLIC OF
Postal Code:	306-120
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14404001
CORRESPONDENCE DATA	
Fax Number:	(919)419-9354
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9194199350
Email:	hip@hultquistip.com
Correspondent Name:	HULTQUIST IP
Address Line 1:	PO BOX 14329
Address Line 4:	RESEARCH TRIANGLE PK, NORTH CAROLINA 27709
ATTORNEY DOCKET NUMBER:	4240-264
NAME OF SUBMITTER:	STEVEN J. HULTQUIST
SIGNATURE:	/Steven J. Hultquist/
DATE SIGNED:	12/15/2014
Total Attachments: 2	

PATENT

source=264_Assignment#page1.tif

source=264_Assignment#page2.tif

ASSIGNMENT

We, SUNG WUK KIM, SEUNG KOOK PARK, YEON JUNG SONG, EUN SUN KIM, HYEY KYUNG AHN, JAE KAP JEONG, and HUNG KEUN LEE, have made an invention the specification of which is described in the U.S. Patent Application No. 14/404,001 filed under the provisions of 35 U.S.C. § 371, based on International Patent Application No. PCT/KR13/00983 filed on February 7, 2013, entitled:

"NEW USES OF MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1
POLYPEPTIDE"

We hereby assign to Hanall Biopharma Co., Ltd., 43, Sangseodang-1gil, Daedeok-gu, Daegu 306-120, Republic of Korea, all ownership and rights in:

- (i) the invention and U.S. Patent Application;
- (ii) non-provisional, continuing, divisional and continuation-in-part applications based on and claiming benefit and/or priority of said U.S. Patent Application; and
- (iii) U.S. Patents on the invention.

We are making this assignment based on our business relationship with Hanall Biopharma Co., Ltd.

We respectfully request the Commissioner for Patents of the United States to issue patents on the invention to:

Hanall Biopharma Co., Ltd.


as owner of the invention and aforementioned patent rights.

We agree to execute any other legal documents that may be required to effectuate this Assignment.

We agree that we will promptly communicate to Hanall Biopharma Co., Ltd. all facts which come to our attention affecting the invention or patent rights.

We agree that we will testify in any interference or litigation involving the invention or patent rights.

We declare that we have not done anything in conflict with this Assignment.



SUNG WUK KIM


Dec. 11th. 2014

Date (mm/dd/yyyy)



SEUNG KOOK PARK

12/5/2014
Date (mm/dd/yyyy)




YEON JUNG SONG

12/03/2014
Date (mm/dd/yyyy)




EUN SUN KIM

12/03/2014
Date (mm/dd/yyyy)




HYEA KYUNG AHN

12/03/2014
Date (mm/dd/yyyy)



JAE KAP JEONG

12/03/2014
Date (mm/dd/yyyy)



HUNG KEUN LEE

12/03/2014
Date (mm/dd/yyyy)